Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of GZR4 in Subjects with Renal Impairment
NCT06547502Phase 1Completed
- Sponsor
- Gan & Lee Pharmaceuticals
- Start
- Jul 2024
- Primary completion
- Aug 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of GZR4 in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Gan & Lee Pharmaceuticals. Primary endpoints: Area Under the Concentration-Time Curve From Time Zero to Infinity, Area Under the Concentration-Time Curve From Time Zero to the Last Measurable Concentration and 1 more. Started Jul 2024; status: completed.
02
Drugs
GZR4
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06547502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06547502.